Ningbo Newbay Medical Technology Co. Ltd. has identified DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Beijing Danatlas Pharmaceutical Technology Co. Ltd. has divulged DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Daewoong Pharmaceutical Co. Ltd. has synthesized DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Artios Pharma Ltd. has divulged DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Moma Therapeutics Inc. has patented DNA polymerase theta (POLθ) inhibitors reported to be useful for the treatment of cancer.

Moma Therapeutics Inc. has reported preclinical results on MOMA-313, a potent and selective DNA polymerase θ (POLθ) inhibitor under development for the treatment of homologous recombinant (HR)-deficient cancers.

Avelos Therapeutics Inc. has divulged DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Nutshell Biotech (Shanghai) Co. Ltd. has identified nitrogen-containing macrocyclic compounds acting as DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Cyteir Therapeutics Inc. has disclosed DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Breakpoint Therapeutics GmbH has identified DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.